Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Imagerie scientifique

Charcot's disease or amyotrophic lateral sclerosis (ALS)

Causes, mechanisms, symptoms and treatments

Last update: 06/12/2024 Reading time: 1min

Amyotrophic Lateral Sclerosis (ALS) or ‘Charcot's Disease’ is a progressive and fatal neuromuscular pathology characterised by the progressive death of motor neurons, the neurons that control walking, speech, swallowing and breathing, among other things. This loss of motor neurons leads to muscular atrophy and progressive paralysis in patients.

Charcot's disease (ALS) is the most common motor neurone disease in adults.

There are two types of motor neuron:

  • Central motor neurons, located in a specific region of our brain, the motor cortex, transmit contraction commands to the spinal cord.
    Peripheral motor neurons, motor neurons located in the spinal cord, transmit motor information to the muscles.
  • The degeneration of these 2 types of motor neuron in ALS leads to the loss of information transmission between the brain and the voluntary muscles, which are therefore no longer solicited, do not contract and atrophy.

Motor neuron damage can sometimes be associated with a characteristic loss of neurons in the frontal and temporal regions of the brain, leading to cognitive and behavioural disorders of varying intensity. In its most severe form, this leads to fronto-temporal dementia (FTD): 15% of patients with Charcot disease also have FTD. The dementia in FTD is not characterised, as in Alzheimer's disease, by memory problems, but by behavioural changes which are at the forefront. This is reflected in changes in patients' social behaviour and personality.

21.06.2022 Understanding Charcot's disease (ALS) in 2 minutes 
Causes

The causes of Charcot's disease - is it hereditary?

For 1 in 10 patients, the origin of the disease is due to hereditary genetic mutations, known as familial cases.

Mécanismes biologiques

The biological mechanisms of Charcot's disease

Charcot's disease or amyotrophic lateral sclerosis (ALS) is a disease affecting motor neurons, the nerve cells that control voluntary movement. These motor neurons gradually degenerate, although the precise mechanisms leading to neuronal death are not yet known. This neurodegenerative disease progresses in a few years to the point of complete paralysis.

Symptoms, progression and life expectancy

The symptoms, progression and life expectancy of Charcot disease

The symptoms of amyotrophic lateral sclerosis (ALS), also known as Charcot's disease, are characterised by complete paralysis of the muscles of the arms, legs, mouth and tongue, as well as the respiratory muscles. This leads to an inability to use one's arms, walk, eat or speak, and to breathing difficulties that gradually set in. The disease appears in adulthood (average age 59 in France) and progresses, on average in 3 to 5 years, to complete paralysis of the muscles, eventually leading to the patient's death, generally from respiratory failure. Depending on the location of the motor neurons affected (cortical neurons, brain stem neurons and/or spinal cord neurons), the symptoms presented may vary from patient to patient, particularly at the start of the disease.

Treatment and diagnosis

Treatment and diagnosis of Charcot disease

The diagnosis of the disease is suspected by a neurologist who, on neurological examination and questioning, finds signs and symptoms of progressive damage to the first and second motor neurons. In all cases, this is characterised by a progressive loss of muscle strength, sometimes associated with muscle wasting, or stiffness in the limbs. To make this diagnosis, the neurologist relies on the results of an examination that records the electrical signals between the neurons and the muscles: an electromyogram. This shows the motor denervation of the muscles as a result of the loss of motor neurons. In order to confirm this diagnosis, it is essential for the neurologist to be able to rule out, by means of further tests, all other possible causes of motor neuron suffering, such as mechanical compression, inflammatory attacks on the motor nerves or any other process that may damage the nerves.

In the case of familial forms (10%), the diagnosis is established with certainty when the patient carries one of the known mutations responsible for the disease. There are currently more than 30 known genes, and at least 1/3 of familial cases still have no identified genes (the proportion varies from one region of the world to another).

To date, there is no cure for Charcot's disease. However, the combination of neuroprotective treatment and multidisciplinary care that addresses all aspects of the disease can slow the progression of symptoms.

Our news on the subject

Une personne écrit sur un tableau
Looking back at the “Brain to Market” Summer School 2024 dedicated to motor neurone disease
From September 9 to 13, the Open Brain School, the education center at Paris Brain Institute, organized the 10th edition of its flagship training program in neuroscience and entrepreneurship—dedicated to fostering innovation. This event brought the...
10.07.2024 Teaching & training
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
schéma
Discovery of a plasma signature of fronto-temporal degeneration and amyotrophic lateral sclerosis linked to a mutation of the C9orf72 gene
A joint study by teams from the Paris Brain Institute at the Pitié-Salpêtrière hospital and from Inria (Rennes and Paris centers) has revealed for the first-time plasma microRNA signatures in individuals with or presymptomatic of fronto-temporal...
12.04.2020 Research, science & health
image
A promising therapeutic approach in amyotrophic lateral sclerosis (ALS)
Paris, October 19th, 2020 - ALS is characterized by the degeneration of motor neurons resulting in a progressive and irreversible deficit in walking and speech, until a complete paralysis of all muscles, including those controlling respiration. The...
10.20.2020 Research, science & health
acetylcholine
Acetylcholinesterase, a potential therapeutic target for ALS
The neuromuscular junction is a zone that enables transfer of information from the nervous system to muscles, and is affected in Amyotrophic Lateral Sclerosis. The team led by Edor Kabashi at the Institut du Cerveau – ICM focused on the role of...
03.24.2017 Research, science & health
Edor Kabashi
Edor Kabashi wins the International Medicine PG Award for Amyotrophic Lateral Sclerosis (ALS) research
The Paulo Gontijo Institute awarded the International Medicine PG Award to Edor Kabashi, team leader at the Brain and Spine Institute – Institut du Cerveau, for his research on the development of new models and new therapeutic avenues for Amyotrophic...
10.26.2016 Research, science & health
See all our news